Nulojix
| Chemical Name | belatacept |
| Dosage Form | Injection (intravenous; 250 mg) |
| Drug Class | Selective T-cell costimulation blockers |
| System | Multiple |
| Company | Bristol Myers Squibb |
| Approval Year | 2011 |
Indication
- Indicated in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids for prophylaxis of organ rejection in adult patients receiving a kidney transplant.